Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 5/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19071002 | 1.00 | LIPE (0.35) | LIPEFAAHEGLN1PPARGKDM4E | |
| SCHEMBL19070813 | 0.88 | USP2 (0.30) | — | |
| SCHEMBL10196266 | 0.88 | USP2 (0.30) | — | |
| SCHEMBL19071632 | 0.87 | MAOA (0.36) | PPARGPOLBSMN1; SMN2 | |
| SCHEMBL10196134 | 0.87 | MAOA (0.36) | PPARGPOLBSMN1; SMN2 | |
| SCHEMBL19070965 | 0.86 | MAPK1 (0.44) | LIPESCN9A | |
| SCHEMBL10196256 | 0.86 | MAPK1 (0.44) | LIPESCN9A | |
| SCHEMBL10196259 | 0.86 | MAPK1 (0.44) | LIPEPPARGSMN1; SMN2SCN9A | |
| SCHEMBL19070882 | 0.86 | MAPK1 (0.44) | LIPEPPARGSMN1; SMN2SCN9A | |
| SCHEMBL10196017 | 0.86 | CYP1A2 (0.39) | CYP3A4MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389066-B1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA LTD (GB) | 2017-07-05 | — | — | EP | disclosed |
| US-8895474-B2 | Herbicidally active cyclopentanediones and derivatives thereof, and their use in controlling weeds | SYNGENTA LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8895474-B2 | Herbicidally active cyclopentanediones and derivatives thereof, and their use in controlling weeds | SYNGENTA LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20120021912-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021912-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | LIPE 482/4885FAAH 24/4885EGLN1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.